CLINTON BYBEE
CIK 1219043 · last filed 2022-08-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$458.72M
Companies
16
Total Filings
39
Lifetime Open-Market Net
$60.75M
Filer Profile
Reported Address
8755 W. HIGGINS ROADSUITE 1025
CHICAGO, IL 60631
Related Filers
KEITH CRANDELL — 113 joint filings, latest 2026-07-06
ROBERT NELSEN — 65 joint filings, latest 2026-07-06
ARCH Venture Fund VII, L.P. — 35 joint filings, latest 2020-12-22
ARCH Venture Partners VII, L.P. — 35 joint filings, latest 2020-12-22
ARCH Venture Partners VII, LLC — 35 joint filings, latest 2020-12-22
ARCH Venture Fund IX Overage, L.P. — 32 joint filings, latest 2025-07-29
ARCH Venture Fund IX, L.P. — 32 joint filings, latest 2025-07-29
ARCH Venture Partners IX Overage, L.P. — 32 joint filings, latest 2025-07-29
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VIR | 10%+ Owner | 208,852 | $10.62 | $2.22M | $0 | 2 | 2022-08-16 |
| BEAM | 10%+ Owner | 2,949,630 | $23.99 | $70.76M | $0 | 1 | 2021-07-02 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | 10%+ Owner | 1,532,049 | $329.83 | $505.32M | $22.40M | 3 | 2021-01-12 |
| PI | Director | 17,125 | $176.82 | $3.03M | $97.7K | 14 | 2020-10-23 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 158,734 | $0.49 | $78.6K | $20.93M | 1 | 2020-09-22 |
| DNLI | 10%+ Owner | 10,668,749 | $21.09 | $225.00M | $0 | 1 | 2019-08-12 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | 10%+ Owner | 430,205 | $0.00 | $172 | -$2.94M | 1 | 2019-07-17 |
| Unity Biotechnology, Inc. (UBX) Delisted | 10%+ Owner | 629,860 | $0.20 | $126.0K | $0 | 1 | 2018-05-07 |
| Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | 10%+ Owner | 2,750,575 | — | — | $0 | 1 | 2017-08-01 |
| XCOM | Director | 1,885,090 | $28.61 | $53.93M | $7.50M | 5 | 2016-10-13 |
| VBI VACCINES INC. (VBIV) Delisted | 10%+ Owner | 134,928 | $0.07 | $8.8K | $0 | 1 | 2015-08-17 |
| PULM | 10%+ Owner | — | $1.41 | — | $0 | 1 | 2015-06-25 |
| Sage Therapeutics, Inc. (SAGE) Delisted | 10%+ Owner | 2,124,699 | $8.68 | $18.44M | $0 | 2 | 2015-06-22 |
| Bellerophon Therapeutics, Inc. (BLPH) Delisted | 10%+ Owner | 64,377 | $0.01 | $773 | $12.76M | 1 | 2015-02-23 |
| AGIO | 10%+ Owner | 3,088,590 | $33.60 | $103.78M | $0 | 2 | 2015-02-23 |
| Juno Therapeutics, Inc. (JUNO) Delisted | 10%+ Owner | 7,347,015 | — | — | $0 | 1 | 2014-12-23 |
Recent Filings · Page 3 of 4
39 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-08-01 | Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | Conv (C) | +21,798,408 | $0 | EDGAR |
| 2017-06-16 | PI | Grant (A) | — | $0 | EDGAR |
| 2017-02-23 | PI | Other (J) | +417 | $0 | EDGAR |
| 2016-10-13 | XCOM | Buy (P) | — | $0 | EDGAR |
| 2016-09-28 | XCOM | Buy (P) | — | $0 | EDGAR |
| 2016-09-15 | XCOM | Buy (P) | — | $0 | EDGAR |
| 2016-08-30 | PI | Mixed | +1,366,735 | $204 | EDGAR |
| 2016-07-26 | PI | Mixed | +1,361,408 | $68 | EDGAR |
| 2016-05-25 | — | Mixed | +2,239,587 | $34.95M | |
| 2015-11-18 | XCOM | Mixed | +1,864,745 | $1.50M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.